IL-17A antibodies
| Title: | IL-17A antibodies |
|---|---|
| Patent Number: | 8,519,107 |
| Publication Date: | August 27, 2013 |
| Appl. No: | 12/915445 |
| Application Filed: | October 29, 2010 |
| Abstract: | Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. |
| Inventors: | Almagro, Juan Carlos (Brookline, MA, US); Della Ducata, Daniela (Martinsried/Planegg, DE); Elloso, Merle (Spring House, PA, US); Luo, Jinquan (Spring House, PA, US); Malia, Thomas (Spring House, PA, US); Naso, Michael (Spring House, PA, US); Obmolova, Galina (Spring House, PA, US); Rauchenberger, Robert (Martinsried/Planegg, DE); Rutz, Mark (Lena-Christ-Strasse, DE); Sweet, Raymond (Spring House, PA, US); Taudte, Susann (Spring House, PA, US); Wu, Bingyuan (Spring House, PA, US); Wu, Sheng-Jiun (Spring House, PA, US) |
| Assignees: | Janssen Biotech, Inc. (Horsham, PA, US) |
| Claim: | 1. An isolated antibody or fragment thereof that binds specifically to human IL-17A, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises the HCDR1, HCDR2 and HCDR3 having the amino acid sequences as shown in SEQ ID NOs:25, 46 and 61, respectively; and the VL region comprises the LCDR1, LCDR2, and LCDR3 having the amino acid sequences as shown in SEQ ID NOs:3, 6 and 22, respectively; and wherein in SEQ ID NO:46, Xaa1 may be Ala, Gly, Thr or Val; Xaa3 may be Asn or Ser; Xaa4 may be Gly, Met, Lys, Ile, Leu or His; Xaa5 may be Leu, Asp, Ala, His, Thr, Gly or Ser; Xaa6 may be Gly or Ser; Xaa7 may be Thr, Gly, Tyr or Asp; Xaa8 may be His, Trp, Tyr or Phe; Xaa9 may be Lys, Thr or Ile; and Xaa10 may be Tyr, Phe or Asn; in SEQ ID NO:61, Xaa may be Met, Leu or Thr; and in SEQ ID NO:22, Xaa is Met, Leu, Thr or Tyr. |
| Claim: | 2. The isolated antibody or fragment of claim 1 , wherein the antibody comprises the HCDR1, HCDR2 and HCDR3 amino acid sequences as shown in: a. SEQ ID NOs: 25, 37 and 58, respectively; b. SEQ ID NOs: 25, 38 and 58, respectively; c. SEQ ID NOs: 25, 39 and 58, respectively; d. SEQ ID NOs: 25, 40 and 58, respectively; e. SEQ ID NOs: 25, 41 and 58, respectively; f. SEQ ID NOs: 25, 42 and 58, respectively; g. SEQ ID NOs: 25, 43 and 58, respectively; h. SEQ ID NOs: 25, 41 and 59, respectively; i. SEQ ID NOs: 25, 41 and 60, respectively; j. SEQ ID NOs: 25, 43 and 60, respectively; k. SEQ ID NOs: 25, 44 and 58, respectively; or l. SEQ ID NOs: 25, 45 and 58, respectively; and the LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in: m. SEQ ID NOs: 3, 6 and 18, respectively; n. SEQ ID NOs: 3, 6 and 19, respectively; o. SEQ ID NOs: 3, 6 and 20, respectively; or p. SEQ ID NOs: 3, 6 and 21, respectively. |
| Claim: | 3. An isolated monoclonal antibody or fragment thereof that binds specifically to human IL-17A that competes for human IL-17A binding with a monoclonal antibody comprising the heavy chain CDR 1, 2 and 3 (HCDR1, HCDR2 and HCDR3) amino acid sequences as shown in SEQ ID NOs: 25, 43 and 60, respectively, and the light chain CDR 1, 2 and 3 (LCDR1, LCDR2 and LCDR3) amino acid sequences as shown in SEQ ID NOs: 3, 6 and 18, respectively. |
| Claim: | 4. The isolated antibody or fragment of claim 3 or 1 , wherein the antibody is fully human. |
| Claim: | 5. The isolated antibody or fragment of claim 3 or 1 , wherein the antibody is conjugated to polyethylene glycol. |
| Claim: | 6. The isolated antibody or fragment of claim 3 or 1 , having an IgG1 or IgG4 isotype. |
| Claim: | 7. The isolated antibody or fragment of claim 3 or 1 , wherein the Fc domain comprises S229P, P235A or L236A mutations in the Fc domain. |
| Claim: | 8. A pharmaceutical composition comprising the isolated antibody or fragment of claim 3 or 1 and a pharmaceutically acceptable carrier. |
| Claim: | 9. An isolated antibody or fragment thereof that binds specifically to human IL-17A comprising a VH and a VL, wherein the antibody comprises: a. the HCDR1, HCDR2 and HCDR3 amino acid sequences as shown in SEQ ID NOs: 25, 43 and 60, respectively and the LCDR1, LCDR2, and LCDR3 amino acid sequences as shown in SEQ ID NOs: 3, 6 and 18, respectively; or b. the VH of SEQ ID NO: 86; or c. the VL of SEQ ID NO: 79; or d. the VH of SEQ ID NO: 86 and the VL of SEQ ID NO: 79. |
| Claim: | 10. An isolated antibody or fragment thereof that binds specifically to human IL-17A, comprising a VH and a VL, wherein the antibody comprises the VH having the amino acid sequence shown in SEQ ID NO: 86. |
| Claim: | 11. The isolated antibody or fragment of claim 10 , wherein the antibody comprises the VL having the amino acid sequence shown in SEQ ID NO: 79. |
| Claim: | 12. An isolated antibody or fragment thereof that binds specifically to human IL-17A, comprising a VH and a VL, wherein the antibody comprises the VL having the amino acid sequence shown in SEQ ID NO: 79. |
| Claim: | 13. An isolated antibody or fragment thereof that binds specifically to human IL-17A, comprising a VH and a VL, wherein the antibody comprises the VH which is at least 95% identical to the VH having the amino acid sequence shown in SEQ ID NO: 86. |
| Claim: | 14. An isolated antibody or fragment thereof that binds specifically to human IL-17A, comprising a VH and a VL, wherein the antibody comprises the VL which is at least 95% identical to the variable region having the amino acid sequence shown in SEQ ID NO: 79. |
| Claim: | 15. An isolated antibody or fragment thereof that binds specifically to human IL-17A, comprising an antibody heavy chain having the amino acid sequence shown in SEQ ID NO: 100. |
| Claim: | 16. An isolated antibody or fragment thereof that binds specifically to IL-17A, comprising an antibody light chain having the amino acid sequence shown in SEQ ID NO: 90. |
| Current U.S. Class: | 53038/823 |
| Patent References Cited: | 5223409 June 1993 Ladner et al. 6649055 November 2003 Whitton et al. 7776540 August 2010 Kastelein et al. 7943744 May 2011 Frendeus et al. 2008/0095775 April 2008 Lewis et al. 2009/0105461 April 2009 Kunz et al. 2010/0021477 January 2010 Tsui et al. WO2006/013107 February 2006 WO2006/054059 May 2006 WO2007/070750 June 2007 WO2008/021156 August 2007 WO2007/106769 September 2007 WO2007/149032 December 2007 WO2008/001063 January 2008 WO2009/003096 December 2008 WO2009/130459 April 2009 WO 2009/068649 June 2009 WO2010/034443 April 2010 |
| Other References: | “Ulcerative colitis—Introduction”, University of Maryland Medical Center, http:// www.umm.edu/patiented/articles/ (2011). cited by applicant Adams, et al., “Recent developments in the PHENIX software for automated crystallographic structure determination,” Journal of Synchrotron Rad., 11: 53-55 (2004). cited by applicant Aggarwal, et al., “Interkeukin-23 Promotes a Distinct CD4T Cell Activation State Characterized by the Production of Interleukin-17,” The Journal of Biological Chemistry, 278(3): 1910-1914 (2003). cited by applicant Alcorn, et al., “TH17 Cells in Asthma and COPD,” Annual Review of Physiology, 72: 495-516 (2010). cited by applicant Al-Lazikani, et al., “Standard Conformations for the Canonical Structures of Immunoglobulins,” Journal of Molecular Biology, 273: 927-948 (1997). cited by applicant Juan C. Almagro, et al., “Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires,” Journal of Molecular Recognition, 17: 132-143 (2004). cited by applicant Barbas, et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,” Proceedings of the National Academy of Science USA, 91: 3809-3813 (1994). cited by applicant Chothia, et al., “Canonical Structure for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology, 196: 901-917 (1987). cited by applicant Curtis, et al., “The Immunopathogenesis of Chronic Obstructive Pulmonary Disease,” Proceedings of the American Thoracic Society, 4: 512-521 (2007). cited by applicant Ely, et al., “Structural basis of receptor sharing by interleukin 17 cytokines,” Nature Immunology, 10(12): 1245-1252 (2009). cited by applicant Emsley, et al., “Coot: model-building tools for molecular graphics,” Acta Crystallography, D60: 2126-2132 (2004). cited by applicant Freese, et al., “Chronic allograft nephropathy-biopsy findings and outcome,” Nephrology Dialysis Transplantation, 16: 2401-2406 (2001). cited by applicant Fujimoto, et al., “Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a TH17 disease?” Journal of Dermatological Science, 50: 240-242 (2008). cited by applicant Gao, et al., “Making artificial antibodies: A format for phage display of combinatorial heterodimeric arrays,” Proceedings of the National Academy of Science USA, 96: 6025-6030 (1999). cited by applicant Genovese, et al., “LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients with Rheumatoid Arthritis,” Arthritis & Rheumatism, 62(4): 929-939 (2010). cited by applicant Gerhardt, et al., “Structure of IL-17A in Complex with a Potent, Fully Human Neutralizing Antibody,” Journal of Molecular Biology, 394: 905-921 (2009). cited by applicant Gudjonsson, et al., “Immunopathogenic mechanisms in psoriasis,” Clinical and Experimental Immunology, 135: 1-8 (2004). cited by applicant Hessel, et al., “Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice,” European Journal of Pharmacology, 293: 401-412 (1995). cited by applicant Holtt, et al., “IL-23/IL-17 Immunity as a Hallmark of Crohn's Disease,” Inflammatory Bowel Diseases, 14(9): 1175-1184 (2008). cited by applicant Hueber, et al., “Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis,” Science Translational Medicine, 2, 52ra72: 1-9 (2010). cited by applicant Hymowitz, et al., “IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding,” The EMBO Journal, 20(19): 5332-5341 (2001). cited by applicant Ivanov, et al., “Interleukin-17 as a drug target in human disease,” Trends in Pharmacological Sciences, 30(2): 95-103(2009). cited by applicant Johansen, et al., “Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin,” British Journal of Dermatology, 160: 319-324 (2009). cited by applicant Kawaguchi, et al., “IL-17 cytokine family,” Journal of Allergy and Clinical Immunology, 114: 1265-1273 (2004). cited by applicant Kolls, et al., “Interleukin-17 Family Members and Inflammation,” Immunity, 21: 467-476 (2004). cited by applicant Kuestner, et al., “Identification of the IL-17 Receptor Related Molecule IL-17RC as the Receptor for IL-17F,” The Journal of Immunology, 179: 5462-5473 (2007). cited by applicant Lefranc, et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Developmental & Comparative Immunology, 27: 55-77 (2003). cited by applicant Anders Linden, “Rationale for targeting interleukin-17 in the lungs,” Current Opinion in Investigational Drugs, 4(11): 1304-1312 (2003). cited by applicant Youhua Liu, “Renal fibrosis: New insights into the pathogenesis and therapeutics,” Kidney International, 69: 213-217 (2006). cited by applicant Loong, et al., “Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection,” Journal of Pathology, 197: 322-332 (2002). cited by applicant Eric Lubberts, “IL-17/TH17 targeting: On the road to prevent chronic destructive arthritis,” Cytokine, 41: 84-91 (2008). cited by applicant Mangan, et al., “Transforming growth factor-β induces development of the TH17 lineage,” Nature, 441: 231-234 (2006). cited by applicant R.B. Mannon, “Therapeutic Targets in the Treatment of Allograft Fibrosis,” American Journal of Transplantation, 6: 667-675 (2006). cited by applicant Maclennan, et al., “Structure-Function Relationships in the Ca2+-Binding and Translocation Domain of SERCA1: physiological correlates in Brody disease,” Acta Physiologica Scandinavica, 163(643): 55-67 (1998). cited by applicant McAllister, et al., Role of IL-17A, IL-17F, and the IL-17 Receptor in Regulating Growth-Related Oncogene-α and Granulocyte Colony-Stimulating Factor in Bronchial Epithelium: Implications for Airway Inflammation in Cystic Fibrosis, The Journal of Immunology, 175:404-412 (2005). cited by applicant Moseley, et al., “Interleukin-17 family and IL-17 receptors,” Cytokine & Growth Factor Reviews, 14: 155-174 (2003). cited by applicant Murata, et al., “Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis of TH17 disease?” Journal of Dermatological Science, 50: 240-242 (2008). cited by applicant Phillips, et al., “Diabetic nephropathy: The central role of renal proximal tubular cells in tubulointerstitial injury,” Histology and Histopathology, 17: 247-252 (2002). cited by applicant Aled Phillips, “The Role of Proximal Tubular Cells in Interstitial Fibrosis: Understanding TGFβ1,” Chang Gung Medical Journal, 30: 2-6 (2007). cited by applicant Racusen, et al., “The Banff 97 working classification of renal allograft pathology,” Kidney International, 55: 713-723 (1999). cited by applicant Read, et al., “Induction of Inflammatory Bowel Disease in Immunodeficient Mice by Depletion of Regulatory T. Cells,” Current Protocols in Immunology, Chapter 15, 15.13 (2001). cited by applicant Randy J. Read, “Pushing the boundaries of molecular replacement with maximum likelihood,” Biological Crystallography, D57: 1373-1382 (2001). cited by applicant Ritz, et al., “Nephropathy of type II diabetes,” Nephrology DialysisTransplantation, 11(Suppl. 9): 38-44 (1996). cited by applicant Shi, et al., “De Novo Selection of High-Affinity Antibodies from Synthetic Fab Libraries Displayed on Phage as pIX Fusion Proteins,” Journal of Molecular Biology, 397: 385-396 (2010). cited by applicant Simonson, et al., “Phenotypic transitions and fibrosis in diabetic nephropathy,” Kidney International, 71: 846-854 (2007). cited by applicant Strong, et al., “Three-Dimensional Structure of Murine Anti-p-azophenylarsonate Fab 36-71. X-ray Crystallography, Site-Directed Mutagenesis, and Modeling of the Complex with Hapten,” Biochemistry, 30: 3739-3748 (1991). cited by applicant Teplyakov, et al., “Epitope Mapping of Anti-Interleukin-13 Neutralizing Antibody CNTO607,” Journal of Molecular Biology, 389: 115-123 (2009). cited by applicant Toda, et al., “Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions,” Journal of Allergy and Clinical Immunology, 111: 875-881 (2003). cited by applicant Tornetta, et al., “Antibody Fab display and selection through fusion to the pIX coat protein of filamentous phage,” Journal of Immunological Methods, 360: 39-46 (2010). cited by applicant Toy, et al., “Cutting Edge: Interleukin 17 Signals through a Heterodimeric Receptor Complex,” The Journal of Immunology, 177: 36-39 (2006). cited by applicant Van Kooten, et al., “Interleukin-17 Activates Human Renal Epithelial Cells in Vitro and Is Expressed during Renal Allograft Rejection,” Journal of the American Society of Nephrology, 9: 1526-1534 (1998). cited by applicant Woltman, et al., “Interkeukin-17 and CD40-Ligand Synergistically Enhance Cytokine and chemokine Production by Renal Epithelial Cells,” Journal of the American Society of Nephrology, 11: 2044-2055 (2000). cited by applicant Weaver, et al., “IL-17 Family Cytokines and the Expanding Diversity of Effector T Cell Lineages,” Annual Review of Immunology, 25: 821-852 (2007). cited by applicant Wright, et al., “Identification of an Interleukin 17F/17A Heterodimer in Activated Human CD4+TCells,” The Journal of Biological Chemistry, 282(18): 13447-13455 (2007). cited by applicant Zhang, et al., “Critical Role of IL-17 Receptor Signaling in Acute TNBS-induced Colitis,” Inflammatory Bowel Diseases, 12(5): 382-388 (2006). cited by applicant GenBank Accession No. NP—002181 (May 1, 2011). cited by applicant GenBank Accession No. NP—055154 (May 14, 2011). cited by applicant GenBank Accession No. NP—703191 (Apr. 10, 2011). cited by applicant |
| Primary Examiner: | Jiang, Dong |
| Attorney, Agent or Firm: | Baumeister, Kirk |
| Accession Number: | edspgr.08519107 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|